CY 2027 Physician Fee Schedule Final Rule: What It Means for Genetic Testing Labs
Short answer: The CY 2027 physician fee schedule final rule, released November 4, 2026, did not set new lab prices, but it confirmed the rules behind them: reductions to Clinical Laboratory Fee Schedule rates are capped at 15% per year from 2027 through 2029, and a duplicate-testing request for information produced no policy.
What the final rule actually settled for labs
Most coverage of the CY 2027 physician fee schedule final rule focuses on physician conversion factors. The AHA reported that the qualifying APM conversion factor falls 1.83% and the non-qualifying factor falls 2.31% versus CY 2026. Those numbers matter for the professional component of pathology and interpretation services, but they are not where molecular labs feel the largest effect.
For laboratories, the relevant content sits in the CMS fact sheet's Clinical Laboratory Fee Schedule section. CMS says it is finalizing conforming regulations for Consolidated Appropriations Act, 2026 amendments that touch the CLFS. Three pieces are covered: data collection, data reporting, and the phase-in of payment reductions for clinical diagnostic laboratory tests.
The most recent reporting period for non-ADLT tests ran from May 1, 2026 through July 31, 2026, using information collected from January 1, 2025 through June 30, 2025. In other words, the rates labs will be paid in 2027 are built on payor data that is already a year or more old by the time the rates take effect.
The 15% cap in plain terms
The most consequential line for finance teams is this one: starting in CY 2027, reductions from CLFS rates based on private payor data are limited to 15% per year through CY 2029. CMS repeats the rule in its preliminary rate fact sheet, which says a test's payment cannot drop more than 15% per year compared with the prior year.
That changes how to read the preliminary numbers. Category averages are potential changes, and the cap limits what any single test can lose in a year. A code with a larger indicated reduction is not necessarily cut in full in 2027. It is, however, on a path that the rules allow to continue through 2029. Budget for three years of stepped reductions rather than a single reset.
How the preliminary rates look by category
CMS published preliminary CY 2027 rates on September 21, 2026. Of 1,947 applicable HCPCS codes, 1,528 have a weighted median from private payor data. Of those, CMS reports 186 higher than CY 2026 rates, 169 equal and 1,171 lower. The average potential change is about 16% lower.
By category, CMS lists chemistry at minus 16%, molecular pathology at minus 22%, genomic sequencing at minus 23%, microbiology and immunology at minus 19.3% each, and proprietary laboratory analysis at minus 2.4%. Genetic testing labs sit in the two steepest categories. For deeper code-level discussion, see our analysis of the preliminary CLFS rates for molecular pathology and our earlier note on the PAMA rate cuts.
Final CLFS rates are the next date that matters
CMS said it will publish final CY 2027 CLFS rates on its website in November 2026. The comment window on the preliminary rates ran 30 days from the September 21 publication. Labs that filed comments should compare the final file against the preliminary file code by code, paying particular attention to any code where CMS moved from a crosswalk or gapfill determination to private payor data, since those are the codes where surprises tend to appear.
A September 15 to 16, 2026 public meeting covered how to set payment for existing tests with no applicable data, using crosswalking or gapfilling. Codes without payor data are the ones whose final rate depends on that process, so keep them separate in any forecast.
The duplicate-testing RFI: no policy, but a signal
The final rule included a request for information on duplicate laboratory testing, imaging and result sharing, addressing siloed results, duplicative testing and interoperability. CMS says it received feedback and may consider it in future rulemaking. No policy was finalized.
Labs should not read that as a closed question. A federal payer asking publicly about duplicate testing is a precursor to edits, and labs already face claim-level scrutiny in this area, as described in our guide to duplicate lab test denials and modifier 91. Genetic labs are exposed in particular where a patient has prior results from another lab that the ordering clinician never received.
What this means for pricing, contracts and RCM
Medicare rates are a reference point for many commercial contracts, so a three-year step-down in the CLFS can pull on commercial negotiations even where the payer is not bound by Medicare. Congressional action remains a separate variable, covered in our piece on the RESULTS Act and PAMA reform, and this post does not assume any outcome there.
Practical steps, offered as operational guidance rather than as anything CMS prescribes: first, load the final November rate file the day it appears and model 2027 revenue by code with the 15% cap applied. Second, flag every code that falls in the genomic sequencing and molecular pathology categories and rank them by Medicare volume. Third, review ordering workflows for prior-result capture, so the lab can document why a repeat test was medically necessary. Fourth, confirm your professional-component billing assumptions against the new conversion factors. Finally, revisit denial benchmarks using the genetic testing denials guide, and see how ScreenMyGene supports pre-submission checks.
What the fact sheet does not say
The CMS fact sheet does not address an efficiency adjustment, prior authorization, or genetic and molecular testing specifically. Labs should read the full Federal Register text of the final rule, CMS-1848-F, before drawing conclusions on those topics rather than inferring policy from silence in a summary.
Frequently asked questions
Did the CY 2027 final rule change how much labs are paid under the CLFS?
Not by itself. CMS says it finalized conforming regulations for Consolidated Appropriations Act, 2026 changes on data collection, reporting and the phase-in of reductions. Final CY 2027 CLFS rates are a separate step; CMS said it will publish them on its website in November 2026, so rate-level answers must wait for that file.
What is the 15% cap?
Starting in CY 2027, reductions from CLFS rates based on private payor data are limited to 15% per year through CY 2029, per the CMS final rule fact sheet. A test's payment cannot fall more than 15% in a year versus the prior year.
Did CMS finalize a policy on duplicate laboratory testing?
No. The final rule included a request for information on duplicate laboratory testing, imaging and result sharing. CMS says it received feedback and may consider it in future rulemaking, but no policy was finalized in this rule, so labs have no new federal duplicate-testing edit to implement yet.
When was the most recent CLFS data reporting period?
The most recent period for non-ADLT tests ran from May 1, 2026 through July 31, 2026. It used information collected from January 1, 2025 through June 30, 2025, according to the CMS fact sheet. That means 2027 rates reflect payor data that is already more than a year old.
Are genetic tests hit harder than other lab tests?
In the preliminary rates, yes on average. CMS reported average potential changes of minus 23% for genomic sequencing and minus 22% for molecular pathology, against minus 16% for chemistry. Proprietary laboratory analysis codes averaged minus 2.4%. The 15% annual cap limits any one year's drop.
This article is educational decision support for laboratories and clinicians and is not legal, coding, reimbursement or medical advice. Payment policies change; verify against the current CMS rule text, fee schedule files and your payor contracts before acting.
Sources: CMS, Calendar Year 2027 Medicare Physician Fee Schedule Final Rule fact sheet; CMS, Preliminary Calendar Year 2027 Medicare Clinical Laboratory Fee Schedule Payment Rates fact sheet; AHA News, "CMS issues CY 2027 physician fee schedule final rule," November 4, 2026.